Table 2.
In‐Hospital Characteristics of All Admissions by Metolazone Use
| Characteristic | All Admissions | Metolazone Use During Admission | P Value | |
|---|---|---|---|---|
| N=13 898 | No (n=12 850) | Yes (n=1048) | ||
| Diuretics | ||||
| Peak diuretic dose during hospitalization in IV furosemide equivalents, mg | 80 (40,80) | 80 (40,80) | 120 (80 160) | <0.001a |
| Last IV diuretic dose before discharge in IV furosemide equivalents, mg | 60 (40,80) | 40 (40,80) | 80 (40 160) | <0.001a |
| Diuretic dose on day of discharge in IV furosemide equivalents, mg | 40 (0,80) | 40 (0,80) | 80 (0,160) | <0.001a |
| Laboratory findings at discharge | ||||
| Sodium, mEq/L | 138.9±4.28 | 139.0±4.19 | 136.8±4.82 | <0.001a |
| Potassium, mEq/L | 4.11±0.51 | 4.13±0.50 | 3.97±0.53 | <0.001a |
| Chloride, mEq/L | 100.6±5.52 | 101.1±5.18 | 95.0±6.43 | <0.001a |
| Creatinine, mg/dL | 1.53±1.22 | 1.46±1.17 | 2.34±1.50 | <0.001a |
| eGFR, mL/min per 1.73 m2 | 56.0±28.3 | 57.5±28.2 | 38.1±25.1 | <0.001a |
| Hemoglobin, g/dL | 10.9±2.0 | 11.0±2.0 | 10.6±2.0 | <0.001a |
| Median change in laboratory values (discharge—baseline) | ||||
| Sodium, mEq/L | 0 (−2.0, 3.0) | 0 (−2.0, 3.0) | −1 (−3.0, 3.0) | <0.001a |
| Potassium, mEq/L | −0.2 (−0.6, 0.3) | −0.2 (−0.6, 0.3) | −0.3 (−0.8, 0.25) | <0.001a |
| Chloride, mEq/L | 0 (−3.0, 3.0) | 0 (−3.0, 3.0) | −3.0 (−8.0, 1.0) | <0.001a |
| Creatinine, mg/dL | 0 (−0.2, 0.1) | 0 (−0.2, 0.1) | 0.1 (−0.2, 0.5) | <0.001a |
| eGFR, mL/min per 1.73 m2 | 0 (−5.1, 10) | 0.9 (−4.8, 11) | −2.0 (−8.8, 3.8) | <0.001a |
| Hemoglobin, g/dL | −0.5 (−1.4, 0.20) | −0.6 (−1.4, 0.1) | −0.40 (−1.2, 0.3) | <0.001a |
| Outcomes at discharge | ||||
| Hyponatremia, % | 13.5 | 12.3 | 28.0 | <0.001a |
| Hypokalemia, % | 7.25 | 6.55 | 15.7 | <0.001a |
| WRF, % | 14.6 | 13.2 | 32.3 | <0.001a |
| Length of stay, days | 9.29±12.4 | 8.88±12.0 | 14.4±15.3 | <0.001a |
Values reported are mean±SD, median (quartile 1 to quartile 3), and percentile. WRF was defined by a ≥20% decrease in eGFR from admission to discharge. eGFR indicates estimated glomerular filtration rate; IV, intravenous; WRF, worsening renal function.
a
Significant P‐value.